CEN Biotech Past Earnings Performance

Past criteria checks 0/6

There is insufficient data on CEN Biotech's performance over the last few years.

Key information

n/a

Earnings growth rate

n/a

EPS growth rate

Pharmaceuticals Industry Growth6.0%
Revenue growth raten/a
Return on equityn/a
Net Marginn/a
Last Earnings Update30 Sep 2022

Recent past performance updates

No updates

Recent updates

In this section we usually display a company’s past earnings and revenues to help investors visualise the trend through time. We also gauge the company’s performance by benchmarking its returns and growth to its industry peers and the wider market. However, CEN Biotech has not provided sufficient past data to assess its track record.

This is quite a rare situation as 97% of companies covered by Simply Wall St do have historical data.

Show section

Revenue & Expenses Breakdown
Beta

How CEN Biotech makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

OTCPK:CENB.F Revenue, expenses and earnings (USD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 221-320
30 Jun 222-330
31 Mar 221-19180
31 Dec 211-19180
30 Sep 2102180
30 Jun 2101180
31 Mar 2101520
31 Dec 2001420
30 Sep 200-630
30 Jun 200-620
31 Mar 200-630
31 Dec 190-630
30 Sep 190-830
30 Jun 190-830
31 Mar 190-730
31 Dec 180-830
30 Sep 180-15120
30 Jun 180-15120
31 Mar 180-14120
31 Dec 170-14120
30 Sep 170-1020
30 Jun 170-920
31 Mar 170-920
31 Dec 160-810
30 Sep 160-310
30 Jun 160-310
31 Mar 160-210
31 Dec 150-210
30 Sep 150-310
30 Jun 150-220
31 Mar 150-320
31 Dec 140-330

Quality Earnings: Insufficient data to determine if CENB.F has high quality earnings.

Growing Profit Margin: Insufficient data to determine if CENB.F's profit margins have improved over the past year.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: Insufficient data to determine if CENB.F's year-on-year earnings growth rate was positive over the past 5 years.

Accelerating Growth: Insufficient data to compare CENB.F's past year earnings growth to its 5-year average.

Earnings vs Industry: Insufficient data to determine if CENB.F's earnings growth over the past year exceeded the Pharmaceuticals industry average.


Return on Equity

High ROE: CENB.F has a negative Return on Equity (0%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.